The Board of Directors of Sanofi Consumer Healthcare India Limited met on April 28, 2026, and approved the unaudited financial results for the quarter ended March 31, 2026. The company reported a robust standalone net profit of ₹678 Million, representing a significant increase of 35.60% compared to the corresponding quarter of the previous year. Revenue from operations for the quarter stood at ₹2,292 Million, marking a year-over-year growth of 32.79%. While domestic sales grew by 15.5% aided by product relaunches, export sales witnessed an exceptional surge of 144.4% on a lower base.

Sanofi Consumer Healthcare India Limited is a dedicated pharmaceutical entity that focuses on a single business segment: the “Pharmaceutical Business”. The company manages well-known consumer healthcare brands such as Dulcoflex, Allegra, and Combiflam. In late 2025, the company appointed Himanshu Bakshi as its Managing Director. Throughout 2025, the company successfully relaunched several key products, including Combiflam Suspension, Allegra Suspension, and Depura Kids, following a voluntary recall in 2024. The company also expanded its reach through strategic distribution partnerships with firms like Emcure Pharmaceuticals to broaden the availability of its cardiovascular and oral anti-diabetic drugs. Significant institutional investors holding stakes in the company include Nippon India Growth Mid Cap Fund, Aditya Birla SL Large Cap Fund, and SBI Dividend Yield Fund.